About Hanmi

한미약품은 창조와 도전을 기치로 신약개발에 매진하는 R&D중심 제약기업입니다.



  • Dec Hanmi Pharmaceutical’s first shipment of ‘AMOSARTAN’ made to MSD
  • Hanmi’s ‘ORASCOVERY’ technology, licensed out to USA
  • Nov Orphan drug designation for LAPS-rhGH applied for
  • Amosartan clinical study is published on BMC Research Note
  • Oct Phase II study of long-acting human growth hormone in European territories
  • JunRetail pharmacists answer that Hanmi's sales reps are the kindest and the most impressive
  • May Hanmi expands its licensing agreement with Merck
  • Apr Hanmi signs a collaboration agreement with Kinex to develop and market a novel anti-cancer drug candidate, KX-01
  • Mar Esomezol receives IR52 Jang Young-Shil Award from KOITA
  • Hanmi's Amosartan ranked the second highest for detailing drugs
  • Feb Hanmi strengthens R&D with a new external collaboration unit
  • Hanmi's Clopidogrel, approved in European countries
  • Jan Hanmi`s Esomezol wins IR52 Jang Young-Shil Award
  • Filed letter with FDA for modified Esomeprazole Capsule
  • R&D reinforcement with a new external collaboration unit (eR&D)